News
RNAZ
3.400
-0.87%
-0.030
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 4h ago
Weekly Report: what happened at RNAZ last week (0803-0807)?
Weekly Report · 2d ago
Virax Biolabs and Transcode Therapeutics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
Barchart · 5d ago
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 08/03 21:05
TransCode Therapeutics Updates Preferred Stock Governance Terms
TipRanks · 08/03 21:02
Weekly Report: what happened at RNAZ last week (0727-0731)?
Weekly Report · 08/03 09:21
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 07/29 21:06
Weekly Report: what happened at RNAZ last week (0720-0724)?
Weekly Report · 07/27 09:22
TransCode Therapeutics Shareholders Approve Key Capital Measures
TipRanks · 07/20 20:51
Weekly Report: what happened at RNAZ last week (0713-0717)?
Weekly Report · 07/20 09:21
TransCode Therapeutics Updates Preferred Stock Ownership Limits
TipRanks · 07/17 21:33
Weekly Report: what happened at RNAZ last week (0706-0710)?
Weekly Report · 07/13 09:21
Top Biotech Gainers: VRAX Jumps 100% After Fosun Deal, FBRX Soars On Vitiligo Data, TRAX On Watch
NASDAQ · 07/10 02:50
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 07/09 17:05
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 07/06 17:05
Weekly Report: what happened at RNAZ last week (0629-0703)?
Weekly Report · 07/06 09:22
TransCode Adjourns Annual Meeting Amid Nasdaq Listing Steps
TipRanks · 07/02 20:34
Top Biotech Gainers: CANF Climbs, RGNT Gears Up For Europe Launch, RNAZ, ELTX On Watch
NASDAQ · 07/02 03:16
Top Biotech Gainers: ABVX Soars On UC Trial Data, PMN Eyes Alzheimer's Catalyst, TRAX In Focus
NASDAQ · 07/01 02:40
Weekly Report: what happened at RNAZ last week (0622-0626)?
Weekly Report · 06/29 09:21
More
Webull provides a variety of real-time RNAZ stock news. You can receive the latest news about Transcode Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About RNAZ
TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. It is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The Company is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact.